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Background: Data describing real-life management and treatment of community-acquired pneumonia (CAP) in
Europe are limited. REACH (NCT01293435) was a retrospective, observational study collecting data on the
management of EU patients hospitalized with CAP.
The purpose of this study was to understand patient and disease characteristics in patients hospitalized with CAP
and to review current clinical practices and outcomes.
Methods: Patients were aged ≥18 years, hospitalized with CAP between March 2010 and February 2011, and
requiring in-hospital treatment with intravenous antibiotics. An electronic Case Report Form was used to collect
patient, disease and treatment variables, including type of CAP, medical history, treatment setting, antibiotics
administered and clinical outcomes.
Results: Patients (N = 2,039) were recruited from 128 centres in ten EU countries (Belgium, France, Germany,
Greece, Italy, the Netherlands, Portugal, Spain, Turkey, UK). The majority of patients were aged ≥65 years (56.4%)
and had CAP only (78.8%). Initial antibiotic treatment modification occurred in 28.9% of patients and was more
likely in certain groups (patients with comorbidities; more severely ill patients; patients with healthcare-associated
pneumonia, immunosuppression or recurrent episodes of CAP). Streamlining (de-escalation) of therapy occurred in
5.1% of patients. Mean length of hospital stay was 12.6 days and overall mortality was 7.2%.
Conclusion: These data provide a current overview of clinical practice in patients with CAP in EU hospitals,
revealing high rates of initial antibiotic treatment modification. The findings may precipitate reassessment of
optimal management regimens for hospitalized CAP patients.
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Community-acquired pneumonia (CAP) has an inci-
dence rate of around 1 case per 1000 population per
year in the EU [1] and is associated with considerable
morbidity and mortality worldwide, with up to 68.8% of
patients requiring hospitalization [1-4]. Previous studies* Correspondence: francesco.blasi@unimi.it
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reproduction in any medium, provided the orshow that patient outcomes are influenced by a number
of factors, of which the decision to hospitalize and rapi-
dity of initiation of antibiotic treatment are most impor-
tant. The decision regarding site of care is critical [5,6]
as low-risk patients may be vulnerable to worsened out-
comes when treated in the hospital environment [6], and
hospitalization for CAP is responsible for up to 80% of
the total costs of this disease [7]. In bacterial pneumonia,
rapid selection and initiation of appropriate antibiotic
therapy is vital, shortening the illness course and signi-
ficantly reducing the risk of complications or mortality
[8]. Treatment decisions are complicated by the diffi-
culty of obtaining a microbiological diagnosis, and empi-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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standard [9]. Further, the ongoing development and
shifting global patterns of antibiotic resistance may com-
promise effectiveness of previously useful antibiotics
[10]. Finally, the choices of therapy available, both gen-
eric and branded, are numerous.
While the factors driving patient outcomes in CAP are
increasingly understood, data on patient morbidity and
mortality and associated resource use in Europe are
scarce. Information is available mainly from individual
countries rather than the whole continent and reports
vary widely or are out of date [11]. Furthermore, com-
prehensive information on CAP management patterns in
the real-life setting across Europe and their impact on
patient outcomes is not available.
Therefore, we performed a retrospective observational
study in ten EU countries (REACH; Retrospective Study
to Assess the Clinical Management of Patients With
Moderate-to-Severe Complicated Skin and Soft Tissue In-
fections (cSSTI) or CAP in the Hospital Setting) designed
to create a better understanding of clinical management
of these infections in response to current, real-world chal-
lenges. The study is a collaboration involving independent
experts in CAP or cSSTI, a health economist, and clinical
investigators across Europe, funded by AstraZeneca. The
cSSTI data are reported separately elsewhere (Garau et al.
submitted).
The CAP component reported here had two main objec-
tives: to collect detailed background data on patients hos-
pitalized with CAP in Europe, and to provide a summary
of clinical practice decisions in these patients and their im-
pact in terms of initial antibiotic treatment modification
rates, associated length of hospital stay and mortality.
Methods
Overview
REACH (NCT01293435) was a multinational, multicentre,
observational, retrospective cohort study of patients hos-
pitalized with CAP. Patients were enrolled from 128 sites
in ten EU countries; Belgium, France, Germany, Greece,
Italy, the Netherlands, Portugal, Spain, Turkey and the UK
(see Additional file 1: Appendix 2 for full list of investiga-
tors). The study was performed according to Good Clini-
cal Practice and the Declaration of Helsinki. All local
ethics committees approved the study protocol. Local le-
gislation relating to written informed consent for non-
interventional studies was followed in each country; in
Germany and Portugal, where this information is man-
datory, written informed consent was collected.
Patients
The population comprised patients with CAP requiring
hospitalization identified between December 2010 and
January 2011. All patients complying with relevant diseasecodes (Additional file 1: Appendix 1) in the World Health
Organization International Classification of Diseases 10th
revision (ICD-10; 2007 version) were included [12]. The
window for hospitalizations could be extended backward
to March 2010 and forward to February 2011 until suffi-
cient patients were identified. Patients to be included were
selected from those identified by using an automatic
randomization tool, in order to avoid selection bias.
Inclusion criteria
The study included adults (≥18 years of age) requiring
treatment with intravenous (IV) antimicrobials. Ra-
diographically confirmed pneumonia and acute illness
(≤7 days’ duration) were required, with at least three of:
new or increased cough; purulent sputum or change
in sputum character; auscultatory findings consistent
with pneumonia; dyspnoea, tachypnoea or hypoxae-
mia (O2 saturation <90% or pO2 <60 mmHg); fever
(>38°C [oral]) or hypothermia (<35°C); white blood cell
count >10,000 cells/mm3 or <4,500 cells/mm3; >15%
band neutrophils irrespective of white blood cell count;
requirement for initial hospitalization or treatment in an
emergency room or urgent care setting.
Exclusion criteria
Patients already participating in a clinical trial or any
other interventional study were not eligible. Patients
with CAP deemed suitable for outpatient therapy with
an oral antibiotic and patients transferred from another
healthcare facility or readmitted with antibiotic use within
2 days were also excluded.
Study variables
Data were collected via an electronic Case Report Form
completed by the investigator. The information collected
included site characteristics; patient demographics; me-
dical history; disease characteristics, including severity
score (Pneumonia Outcomes Research Team/Pneumonia
Severity Index [PORT/PSI] [13]; CURB-65 [14]) and
microbiological diagnosis; treatment setting; disease
course and outcomes; antibacterial and other treatments
before and during hospitalization and health resource
consumption.
Statistical methods and data interpretation
As the study is descriptive, no formal sample size cal-
culations were performed. The aim was to recruit ap-
proximately 200–300 patients per disease per country to
achieve a representative spread of patients.
The primary outcome measure was the initial anti-
biotic treatment modification rate. The initial antibiotic
was the first IV antibiotic administered on admission to
the hospital. ‘Initial antibiotic treatment modification’
was defined as a change in initial antibiotic treatment
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with other drugs, non-suitability of the initial antibiotic
based on the results of microbiological tests or changes
to or additions of new agents in a subsequent line, alone
or in combination. Cases of streamlining (also known as
de-escalation, defined as change to narrower-spectrum
antibiotics upon patient improvement or confirmed mi-
crobiological diagnosis) were also recorded, but consi-
dered separately. Cases of patient death while on initial
antibiotic treatment were also recorded.
Several antibiotic treatment modifications in the same
patient were counted as a single case. Changes in dose
or frequency of an existing antibiotic (considered as dose
escalation or adaptation) and removal of an antibiotic
from a combination and adaptation of the dose or fre-
quency of the remaining antibiotic were not considered
treatment modification.
For recording time to clinical stability, investigators
were asked to report what criteria they had followed:
Halm criteria [15], switch from IV to oral therapy or
other criteria defined by the investigator.
Results
Patient population
The analysis population included 2,039 patients. Patient
disposition is shown in Figure 1. The majority of patients
were enrolled between November 2010 and February 2011.
Numbers of sites and numbers of patients per country
are shown in Additional file 1: Table S1. Some countries
did not achieve the target sample size of 200–300 pa-
tients; in Germany, the requirement for signed informed
consent in a retrospective study precluded wider patient
recruitment, leading to considerably fewer patients than
other countries (n = 50), while in Portugal, changes inFigure 1 Patient flow.data protection laws delayed initiation, and in the UK,
supply delays for some patient records necessitated their
exclusion. Patient demographics and baseline character-
istics are shown in Table 1.
Medical history and disease characteristics are shown
in Table 2. The mean age of patients differed conside-
rably between patients with and without comorbidities
(67.8 years and 52.6 years, respectively). Over half of the
patients had received medications in the 3 months prior
to admission.
Characteristics of the index CAP infection are
shown in Table 3. The majority of patients had
no known recent contact with the healthcare system,
having been resident in a private house or apartment
prior to admission, while 12% of patients had been
resident in settings commonly linked with healthcare-
associated pneumonia (HCAP), such as in a nursing
home. Antibiotic treatment of the index infection
prior to hospitalization occurred in 23.5% of patients,
the most common antibiotic classes used being peni-
cillins or penicillin–β-lactamase inhibitor combina-
tions (9.3%), fluoroquinolones (4.5%), cephalosporins
(4.0%) and macrolides (3.5%).
Diagnostic information
Diagnostic information is shown in Additional file 1:
Table S2. Although microbiological testing was conduc-
ted in all but one patient (Additional file 1: Table S2a),
only 582 (28.5%) patients had a microbiological diagno-
sis available (Additional file 1: Table S2b). The most
commonly isolated organism in the full analysis popula-
tion was Streptococcus pneumoniae (39.2%). In patients
with bacteraemia, this organism accounted for the ma-
jority of microbiological diagnoses (63.8%).
Table 1 Patient demographics of analysis population
Characteristic
Age, years, mean (SD) [median] 64.5 (18.5) [68.0]
≥65 years, n (%) 1,150 (56.4)
Female, n (%) 843 (41.3)
Ethnic origin, n (%)
White 1,573 (77.1)
Non-white 51 (2.5)
Unknown/missing 51 (2.5)
Not applicable* 364 (17.9)
Residential/health status, n (%)
Private house or apartment 1,720 (84.4)
Nursing home 145 (7.1)
Home care through healthcare agency 32 (1.6)
Previous admission to hospital with CAP
(last 3 months)
99 (4.9)
Immunocompromised/immunosuppressed 72 (3.5)
Haemodialysis 6 (0.3)
Chemotherapy for active cancer 30 (1.5)
Other 43 (2.1)
Unknown 85 (4.2)
Smoking status, n (%)
Non-smoker 704 (34.5)
Ex-smoker 553 (27.1)
Occasional smoker 42 (2.1)
Habitual smoker 463 (22.7)
Unknown 277 (13.6)
* All patients in this category were from France, where this question is not
permitted in clinical studies. The discrepancy from the total number of
patients for France (n = 366) arises because this information was actually
recorded for two patients in France.
SD: standard deviation.
Table 2 Medical history and disease characteristics
Characteristic
Relevant medical conditions at hospitalization (index visit) (≥5% of
analysis population), n (%)
Any relevant condition 1,598 (78.4)
Respiratory disease 689 (33.8)
Diabetes 369 (18.1)
Congestive heart disease 336 (16.5)
Cancer/malignancy 237 (11.6)
Peripheral vascular disease 183 (9.0)
Renal disease 147 (7.2)
Other relevant conditions* 684 (33.5)
Medication history in the 3 months prior to hospitalization, n (%)
Any prior medication 1,143 (56.1)
Antibiotics/antivirals 395 (19.4)
Anticoagulants 301 (14.8)
Immunosuppressants/immunomodulators 151 (7.4)
NSAIDs 137 (6.7)
Any other relevant therapies* 379 (18.6)
Unknown 146 (7.2)
Patient hospitalized for any reason in the 3 months prior
to index visit, n (%)
204 (10.0)
Invasive surgical treatment in the 3 months prior to index
visit, n (%)
33 (1.6)
Time since previous date of hospitalization, days, mean
(SD) [median] (n = 182)
37.7 (24.0)
[33.5]
Time since symptom start date to hospitalization (index
visit), days, mean (SD) [median] (n = 1,905)
4.9 (9.1) [3.0]
Time since date of hospitalization (index visit) to first
diagnosis date, days, mean (SD) [median] (n = 1,948)
0.5 (4.6) [0.0]
* As defined by the investigator.
NSAIDs: non-steroidal anti-inflammatory drugs; SD: standard deviation.
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In total, 128 sites were included. A large number of uni-
versity (teaching) hospitals were included (n = 54; 42.2%).
Almost all sites were publicly funded (n = 124; 96.9%) and
the majority were large (>500 beds: n = 91; 71.1%). Partici-
pating investigators were most commonly pneumologists
(n = 63; 49.2%) or infectious diseases specialists (n = 35;
27.3%). Similar numbers of patients were treated in uni-
versity and non-university hospitals (958 [47.0%] versus
1,081 [53.0%], respectively) and there were no major dif-
ferences in patient population between hospital types.
Overall use of the PORT/PSI and CURB-65 illness severity
scoring systems was low and was more common in uni-
versity hospitals than in non-university hospitals: PORT/
PSI (30.3% versus 5.9%, respectively) and CURB-65 (39.0%
versus 14.2%, respectively).
Antibiotics were most frequently administered on the
first day of hospitalization (90.0% of patients; n = 1836),with 7.3% of patients (n = 149) receiving antibiotics on the
second day. Antibiotics were administered empirically in
1,918 (94.1%) of patients. An analysis of antibiotic therapy
administered is presented in Additional file 1: Table S3.
Up to 48 different antibiotic agents (alone or in combin-
ation) were reported to have been used, the most frequent
at initial line being amoxicillin-clavulanate (n = 409;
20.1%). The most common antibiotic families at initial line
(whether used as monotherapy or in combinations) were
penicillins or penicillin plus β-lactamase inhibitor combi-
nations (54.7%), fluoroquinolones (29.0%), cephalosporins
(29.5%) and carbapenems (1.8%). The mean overall treat-
ment duration (calculated as start date of initial-line anti-
biotic to end date of last-line antibiotic) was 10.0 days
(SD: 6.6; median: 9.0).
Clinical outcomes
Clinical outcomes are shown in Table 4. The most com-
mon reasons for initial antibiotic treatment modification
Table 3 Characteristics of index CAP infection
Characteristic
Type of CAP, n (%)
CAP* 1,607
(78.8)
HCAP† 245 (12.0)
Immunocompromised/immunosuppressed 72 (3.5)
Other 43 (2.1)
Unknown 85 (4.2)
Radiographic findings suggestive of bacterial pneumonia, n (%)
Infiltrate 1,168
(57.3)
Consolidation 947 (46.4)
Pleural effusion 319 (15.6)
Other 100 (4.9)
Unknown 16 (0.8)
Signs of acute illness at diagnosis, n (%)
New or increased cough 1,575
(77.2)
Purulent sputum or change in sputum character 1,053
(51.6)
Auscultatory findings consistent with pneumonia 1,492
(73.2)
Dyspnoea, tachypnoea, or hypoxaemia 1,491
(73.1)
Fever or hypothermia 1,317
(64.6)
White blood cell count >10,000 cells/mm3 or <4,500
cells/mm3
1,352
(66.3)
Prognosis based on severity indices
PORT/PSI
Total, n (%) 354 (17.4)
Score, mean (SD) 3.5 (1.1)
I, n (%) 18 (0.9)
II, n (%) 53 (2.6)
III, n (%) 83 (4.1)
IV, n (%) 148 (7.3)
V, n (%) 52 (2.6)
CURB-65
Number of patients (%) 527 (25.8)
Score, mean (SD) 2.2 (1.1)
* Residence in private house or apartment only.
† Responses considered HCAP were: residence in a nursing home, home care
through a healthcare agency, previous admission to hospital with CAP
(last 3 months), haemodialysis or chemotherapy for active cancer, with the
exception of immunocompromised/immunosuppressed.
CAP: community-acquired pneumonia; HCAP: healthcare-associated
pneumonia; PORT/PSI: Pneumonia Outcomes Research Team/Pneumonia
Severity Index; SD: standard deviation.
Table 4 Clinical outcomes (full population)
Outcome
Initial antibiotic treatment modification, n (%), for
reasons:*
589 (28.9)
Insufficient response/treatment failure 244 (12.0)
Adverse events 41 (2.0)
Possible interaction with other treatment 1 (<0.1)
Other 149 (7.3)
Unknown 47 (2.3)
No reason reported 107 (5.2)
Death while on initial therapy 63 (3.1)
Streamlining (de-escalation) of therapy†, n (%) 105 (5.1)
Time to initial treatment modification, days, mean (SD)
[median] (n = 760)
5.0 (3.8) [4.0]
Number of antibiotic therapy courses, n (%)
1 1,086 (53.3)
2 644 (31.6)
3 190 (9.3)
>3 116 (5.7)
Time to clinical stability, days, mean (SD) [median] (n =
1,603)
5.6 (5.1) [4.0]
Based on Halm criteria (n = 588) 5.3 (5.4) [4.0]
Based on switch from IV to oral therapy (n = 738) 5.5 (4.1) [5.0]
Based on other criteria (n = 278) 6.4 (6.6) [5.0]
Length of stay, days, mean (SD) [median] (n = 1,978)‡ 12.6 (10.6)
[10.0]
Patients admitted to the ICU (n = 267)§ 19.1 (17.1)
[14.0]
Patients not admitted to the ICU (n = 1,691)§ 10.9 (7.5)
[9.0]
Discharged from hospital, n (%) 1,836 (90.0)
Reinfection/recurrence, n (%)¶ 94 (4.6)
Home-based care after discharge, n (%) 73 (3.6)
Duration of home-based care, days, mean (SD) [median]
(n = 38)
14.7 (15.0)
[7.5]
Mortality rate, n (%) 147 (7.2)
* If multiple reasons are reported, the more clinically relevant reasons were
selected first as the primary reason for change. The ordering of reasons from
most relevant to least relevant are: Adverse event, Insufficient response/
treatment failure, Possible interaction with other treatment, Other, Unknown.
† De-escalation of treatment to narrower-spectrum antibiotics upon patient
improvement or confirmed microbiological diagnosis.
‡ Includes duration of all hospitalizations for patients with recurrences.
§ Does not include duration of all hospitalizations for patients
with recurrences.
¶ Refers to patients hospitalized again (due to CAP) after initial discharge.
IV: intravenous; SD: standard deviation.
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verse events (2.0%). In some patients, the reason
recorded was ‘Other’ or ‘Unknown’, or no reason was
reported. On case-by-case review by the investigators,
these were found not to be related to clinical improve-
ment, the availability of a microbiological diagnosis or
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‘No reason reported’ categories, time to antibiotic treat-
ment modification was <4 days in 37.6% (n = 114) of pa-
tients, ≥4 days in 62.0% (n = 188) and unknown in 0.3%
(n = 1). The median length of stay in hospital, including
all hospitalizations for patients with recurrences, was
10.0 days (mean: 12.6 days; SD: 10.6). If recurrences
were excluded, the median length of stay was 9.0 days
(mean: 12.1 days; SD: 9.8).
The distribution of time to clinical stability according
to any of the criteria is shown in Figure 2. The majority
of patients reached clinical stability on days 2–5. Ap-
proximately half of the patients with clinical stability
data (n = 1,604) achieved clinical stability early in the
course of treatment (day ≤4) (51.9%; n = 833), and 97.1%
had achieved clinical stability on or before day 15. How-
ever, a small percentage (0.7%) of patients had not
achieved clinical stability by day 30. Clinical failure (de-
fined as acute haemodynamic deterioration or death, or
any other criterion considered by the investigator to be
indicative of clinical failure) occurred in 355 patients
(17.4%). Of these, the failure was related to CAP in 239
patients (67.3%), unrelated in 85 patients (23.9%) and for
unknown reasons in 31 patients (8.7%).
Initial antibiotic treatment modification rates by initial
antibiotic agent for the most common antibiotic combina-
tions and monotherapies are shown in Additional file 1:
Table S3. Rates differed widely between antibiotics, with
no obvious pattern. Clinical outcomes according to dis-
ease characteristics are shown in Table 5. Initial antibiotic
treatment modification rates were greater in patients with
HCAP (31.8%) and immunocompromised/immunosup-
pressed patients (40.3%) than in patients with CAP
(28.4%). Mortality rates were also higher in these sub-
groups (HCAP: 16.3%; immunocompromised/immuno-
suppressed: 9.7%) compared with CAP (5.5%). Similarly,
high initial antibiotic treatment modification rates wereFigure 2 Distribution of patients according to time to clinical stabilityobserved in patients with comorbidities versus those with-
out. Worsened clinical outcomes were observed with in-
creased severity of illness as measured by CURB-65 and
PORT/PSI scores, albeit with small patient numbers. For
patients with vaccine data recorded, neither influenza vac-
cination nor pneumococcal vaccination had a significant
impact on outcomes. Mortality for the full population was
7.2%. Mortality varied across the different countries;
Belgium, 12.0% (n = 23/191); France, 5.2% (n = 19/366);
Germany 0% (n = 0/50); Greece 2.3% (n = 5/215); Italy, 1%
(n = 3/300); the Netherlands, 10.8% (22/203); Portugal,
15.7% (n = 19/121); Spain, 6.8% (n = 19/279); Turkey, 8.5%
(n = 17/200) and the UK 17.5% (n = 20/114).
Clinical outcomes in patients attending recurrently with
the same infection
In 94 patients (4.6%), the index CAP infection was a re-
currence of a previously hospitalized CAP episode. The
initial antibiotic treatment modification rate in these pa-
tients was 34.0% (n = 32). The median duration of hospital
stay was 11.0 days (n = 94) and the median time to clinical
stability was 5.0 days (n = 78) (Table 5).
Discussion
CAP-associated morbidity and mortality are consider-
able and particularly common in patients hospitalized
with CAP [16]. The REACH study gathered data on
underlying characteristics and treatment patterns in pa-
tients hospitalized with CAP in a variety of clinical set-
tings across 128 hospitals in ten EU countries. We found
an unexpectedly high overall rate of initial antibiotic
treatment modification (28.9%), with the majority of the
patients treated empirically. Rates of initial antibiotic
treatment modification and associated outcomes, such
as overall mortality, were increased in patients with
more complicated or more severe illness, such as those
patients with a PORT/PSI score of V or ‘severe’ CURB-.
Table 5 Clinical outcomes according to disease characteristics
Outcome Type of CAP Recurrence Comorbidities Severity
PORT/PSI risk score CURB-65 risk groups
CAP only
(n = 1,607)
HCAP
(n = 245)
Immuno-
compromised/
immuno-
suppressed
(n = 72)
With
(n = 94)
Without
(n = 1,548)
With
(n = 1,598)
Without
(n = 441)
I
(n = 18)
II
(n = 53)
III
(n = 83)
IV
(n = 148)
V
(n = 52)
Mild (0–1)
(n = 154)
Moderate (2)
(n = 185)
Severe
(3–5)
(n = 176)
Initial
antibiotic
treatment
modification,
n (%)
456 (28.4) 78 (31.8) 29 (40.3) 32 (34.0) 409 (26.4) 473 (29.6) 116 (26.3) 6 (33.3) 15 (28.3) 19 (22.9) 42 (28.4) 19 (36.5) 37 (24.0) 47 (25.4) 55 (31.3)
Streamlining,
n (%)
72 (4.5) 21 (8.6) 9 (12.5) 8 (8.5) 82 (5.3) 84 (5.3) 21 (4.8) 0 4 (7.5) 6 (7.2) 6 (4.1) 4 (7.7) 4 (2.6) 7 (3.8) 6 (3.4)
Reinfection/
recurrence,
n (%)
70 (4.4) 16 (6.5) 5 (6.9) 94 (100) 0 88 (5.5) 6 (1.4) 0 2 (3.8) 4 (4.8) 9 (6.1) 5 (9.6) 2 (1.3) 11 (5.9) 12 (6.8)
Length of stay,
days, median
9.0
(n = 1,558)
10.0
(n = 235)
12.0
(n = 71)
11.0
(n = 94)
9.0
(n = 1,548)
10.0
(n = 1,555)
8.0
(n = 423)
8.0
(n = 18)
8.0
(n = 53)
10.0
(n = 80)
10.0 (n = 148) 13.0
(n = 51)
8.0
(n = 153)
9.5
(n = 180)
10.0
(n = 175)
Time to
clinical
stability, days,
median
4.0
(n = 1,284)
4.0
(n = 182)
5.0
(n = 55)
5.0
(n = 78)
4.0
(n = 1,295)
4.0
(n = 1,258)
4.0
(n = 345)
3.5
(n = 18)
3.0
(n = 43)
4.0
(n = 63)
5.0 (n = 139) 7.0
(n = 40)
4.0
(n = 137)
5.0
(n = 156)
5.0
(n = 142)
Mortality rate,
n (%)
89 (5.5) 40 (16.3) 7 (9.7) 1 (1.1) 1 (0.1) 128 (8.0) 19 (4.3) 0 1 (1.9) 7 (8.4) 6 (4.1) 11 (21.2) 6 (3.9) 12 (6.5) 29 (16.5)
CAP: community-acquired pneumonia; HCAP: healthcare-associated pneumonia; PORT/PSI: Pneumonia Outcomes Research Team/Pneumonia Severity Index; SD: standard deviation.
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tients and patients with recurrent infections or comor-
bidities. Additionally, patients with HCAP had a much
higher mortality rate of 16.3% compared with 5.5% in
patients with CAP. Total mortality in REACH appears
low at 7.2% but is consistent with data published pre-
viously for patients with PORT scores [17,18]. However,
it may be that REACH patients without a measure of
severity (PORT/PSI or CURB-65) actually had less se-
vere disease globally.
Comparison with previous studies is complicated because
different definitions of treatment modification and treat-
ment failure are employed. Indeed, a 2009 review of treat-
ment failure in patients with CAP across Europe found a
wide variation (2.4–31%) in reported rates (including both
early and late failure) [19]. In studies with treatment failure
defined as per the definition of initial antibiotic treatment
modification used in REACH, treatment failure rates align
closely with the rate of initial antibiotic treatment modifica-
tion observed [17,18].
A health economic analysis of our study showed that
initial antibiotic treatment modification is associated
with higher use of resources compared with no modifi-
cation of initial antibiotic treatment (Ostermann et al.
submitted). Therefore, it is critically important that man-
agement decisions for patients with CAP incorporate
measures that reduce the likelihood of initial antibiotic
treatment modification, including selection and rapid
initiation of the most effective antibiotic agent, efficient
diagnostic methods and early identification of patients
with additional concerns. Initiatives aimed at improving
empiric treatment strategies and microbiological steward-
ship may help in this respect.
The broad range of potential pathogens implicated in
CAP and the difficulty in obtaining a precise microbio-
logical diagnosis complicate treatment of CAP. In this
study, initial treatment decisions were empiric in 94.1%
of patients. A further complication is the wide range of
treatment options: 48 different antibiotic regimens were
reported in this study.
Although almost every patient underwent a microbio-
logical test, the diagnosis rate was only 28.5%. The most
common organism identified was S. pneumoniae, which
follows previous studies [8,20-24]. Interestingly, high per-
centages of less common pathogens, such as S. aureus
(7.2%) and Pseudomonas aeruginosa (7.0%), were observed.
A Swedish study found that these pathogens were more
common in patients with higher CRB-65 scores [20], and a
European review of patients with CAP admitted to inten-
sive care [25] observed S. aureus (7.0%) and Gram-
negative enteric bacilli (8.6%) more frequently than in the
whole population [8]. In patients with bacteraemia in
REACH, the spectrum of pathogens was more homoge-
neous, being dominated by S. pneumoniae (n = 74; 63.8%).Compared with previous studies [26,27], a low proportion
of resistant pathogens was reported in our study (two
patients with penicillin-resistant S. pneumoniae [0.3%] and
12 with methicillin-resistant S. aureus [2.1%]).
Previous studies show that adherence to guidelines for
antibiotic therapy for CAP [6,28] can reduce hospital
length of stay [29,30], costs [30,31] and mortality [32].
The European Respiratory Society (ERS), in collaboration
with The European Society for Clinical Microbiology and
Infectious Disease (ESCMID), recommends penicillins,
with or without β-lactamase inhibitors, or cephalosporins,
administered in combination with newer macrolides for
patients hospitalized with CAP [5]. Although there were a
large number of different initial antibiotic regimens used
in REACH, the majority of treatment decisions were
consistent with these guidelines.
Interestingly, several of the most common antibiotic
classes (penicillins plus macrolide, 32.3%; cephalosporin
[excluding cefuroxime] plus fluoroquinolone, 31.3%) were
associated with initial antibiotic treatment modification
rates slightly higher than the average for all treatments.
This may reflect inappropriate initial treatment choices
for the infecting pathogen. A further possible explanation
is higher use of certain antibiotics in patients with more
severe illness, who may have been predisposed to initial
antibiotic treatment modification. It should be noted that
the initial antibiotic treatment modification rates reported
for antibiotic classes may not generalize to individual
agents within that class.
Our study had a number of limitations. The retrospec-
tive design may have resulted in inconsistent outcomes
assessment between investigators due to differences in
interpretation. However, the potential problem of incom-
plete information in some patient records was not com-
mon, generally occurring in ≤7% of patients (although the
reason for initial antibiotic treatment modification was
‘Other’, ‘Unknown’ or was not reported in 14.8% of pa-
tients). The small patient numbers in some of the sub-
groups limit the possibility of making firm conclusions.
Patient recruitment varied widely between countries owing
to differences in ethical requirements. Also, the included
countries were mainly western European, and so may not
be fully representative of Europe as a whole.
In summary, this large, Europe-wide study provides the
most current data to further describe patient characteris-
tics and clinical management of patients hospitalized with
CAP in this region. The findings reveal the enormous het-
erogeneity in clinical management patterns. Initial anti-
biotic treatment modification occurred in almost one-third
of affected patients, and was more common in patients
with comorbidities than in those without. Therefore, the
authors believe that a reassessment of optimal manage-
ment regimens should be undertaken and new therapies
may be required to address this unmet need.
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